Loading clinical trials...

Holter of Movement in Patients with SMA Undergoing Treatment. | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Holter of Movement in Patients with SMA Undergoing Treatment.

Holter of Movement in Patients with Type 2 or 3 Spinal Muscular Atrophy When Initiating Treatment with Spinraza ° or Risdiplam. Acti-SMA Study.

NCT04888702•Centre Hospitalier Universitaire de Liege

View on ClinicalTrials.gov

Summary

Acti-SMA is a multi-centric academic study. It aims to monitor the progress of patients with spinal muscular atrophy under treatment with Spinraza° or risdiplam. First, we want to quantify improvement of both ambulant and non-ambulant patients under treatment. A secondary objective would also be to identify suitable accelerometric measurements that are sensitive to change but also well correlated to other clinical scores.

Eligibility

Age

6 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Genetically confirmed spinal muscular atrophy.
•Treatment by Spinraza ° or by risdiplam planned.
•Over 6 years old.
•Signed informed consent.

Exclusion Criteria

•\- Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.

Locations (3)

Centre Hospitalier Régional de la Citadelle

Liège, Liège, Belgium

Erasme Hospital - Cliniques universitaires de Bruxelles

Brussels, Belgium

National Clinical Hospital for Children Neurohabilitation "Dr Nicolae Robanescu"

Bucharest, Romania

Key Dates

Start Date

August 8, 2018

Primary Completion Date

January 30, 2025

Completion Date

May 30, 2025

Last Updated

February 12, 2025

Enrollment

ESTIMATED participants

Conditions

Spinal Muscular Atrophy

Interventions

Actimyo

DEVICE

Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy

NCT06321965

Spinal Muscular Atrophy

View study

RECRUITINGNA

Long Read Analysis in Spinal Muscular Atrophy - LOREASI

NCT07332702

Spinal Muscular Atrophy (SMA)

View study

RECRUITINGPHASE3

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Holter of Movement in Patients with SMA Undergoing Treatment.

Inclusion Criteria

Exclusion Criteria

Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy

Long Read Analysis in Spinal Muscular Atrophy - LOREASI

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Respiratory Functions, Thoracoabdominal Movements and Exercise Capacity in Neuromuscular Diseases

Outpatient Rehabilitation Intervention for Young Children With SMA